Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Chronic inflammatory demyelinating polyneuropathy
Economic impact of diagnostic testing
9 evidence topics · 9 sources
Misdiagnosis in 59 consecutive patients referred to a US center with a diagnosis of CIDP
“A retrospective study of 59 consecutive patients referred with a diagnosis of CIDP was performed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Forty-seven percent of patients referred with a diagnosis of CIDP failed to meet minimal CIDP diagnostic requirements.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients frequently reported improvements after being treated with immunotherapy, even if the CIDP diagnosis was incorrect.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Over-reliance on subjective patient-reported perception of treatment benefit, liberal electrophysiologic interpretation of demyelination, and placing an overstated importance on mild or moderate cytoalbuminologic dissociation are common diagnostic errors.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Electrodiagnostic interpretation errors in 86 referred patients
“Thirty-nine of 86 patients were found not to have CIDP. Initial electrodiagnostic data quality was generally acceptable, but initial electrodiagnostic conclusions were confirmed in only 45% of misdiagnosed studies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Overdiagnosis and immunoglobulin exposure before referral at a Dutch tertiary center
“A referral diagnosis of CIDP was revised in 32% of patients (31/96; overdiagnosis).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the overdiagnosed patients, 20% of muscle weakness was asymmetric, 48% lacked proximal muscle weakness, 29% only had distal muscle weakness, 65% did not fulfil the electrodiagnostic criteria for CIDP, 74% had an elevated cerebrospinal fluid (CSF) protein level, and 97% had another type of neuropathy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment Before referral, 52% of overdiagnosed patients ( n = 16) were treated for CIDP with intravenous immunoglobulins (IVIg; n = 12), corticosteroids ( n = 1), or IVIg and corticosteroids ( n = 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Initial misdiagnosis and diagnostic delay in 1056 patients from eight countries
Electrodiagnostic testing before immunoglobulin initiation in 3975 US claims patients
“Of 32,090 patients with CIDP identified, 3975 (mean age 57 years) subsequently initiated IVIG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CIDP-related laboratory/diagnostic procedures were performed in approximately 20– > 40% of patients in the 3 months prior to IVIG initiation (63.7% underwent electrodiagnostic/nerve conduction testing in the 6 months prior to IVIG initiation).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, some patients received IVIG therapy in the absence of electrodiagnostic or nerve conduction tests.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Electrophysiological findings as a US payer requirement for immunoglobulin coverage
“Several US payers mandate positive electrophysiological findings on at least three of four tests (per guidelines from the American Academy of Neurology [AAN]) as part of medical necessity for CIDP treatment, particularly intravenous immunoglobulin (IVIg)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment cost in Charcot-Marie-Tooth disease misdiagnosed as CIDP compared with the cost of genetic testing
“Among 1104 CIDP cases, we identified 35 CMT patients misdiagnosed as CIDP (3.2%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment cost in these 35 misdiagnosed patients was estimated at 4.6 million euros (M€), whereas the cost of CMT genetic analysis in 1104 patients was estimated at 2.7 M€.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Importantly, the cost of treating these 35 misdiagnosed patients was significantly higher than the cost of performing CMT genetic analysis in 1104 patients (4.6 M€ vs. 2.7 M€), suggesting that CMT genetic investigations should be more widely used before diagnosing CIDP.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Costs of POEMS syndrome misdiagnosed as CIDP and cost-effectiveness of VEGF testing
“Delay in diagnosis is common with 55% of patients initially incorrectly diagnosed with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment associated with an incorrect CIDP diagnosis led to total wasted healthcare expenditures of between £808 550 and £1 111 756 across our cohort, with an average cost-per-POEMS-patient misdiagnosed of £14 701 to £20 214.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Introducing mandatory VEGF testing for patients with acquired demyelinating neuropathy would lead to annual cost-savings of £107 398 for the National Health Service and could prevent misdiagnosis in 16 cases per annum.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote